莫扎伐普坦盐酸盐
莫扎伐普坦盐酸盐 性质
| 储存条件 | 2-8°C |
|---|---|
| 溶解度 | 在DMSO中的溶解度≥15mg/mL |
| 形态 | 粉末 |
| 颜色 | 白色至棕褐色 |
| InChIKey | MOROBKPIULFQDC-UHFFFAOYSA-N |
| SMILES | Cl.CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c4ccccc14 |
莫扎伐普坦盐酸盐 用途与合成方法
IC50: 14 nM (Vasopressin V 2 receptor); 1.2 μM (Vasopressin V 1 receptor)
Mozavaptan (OPC-31260) inhibits AVP binding to binding to rat liver (V1 receptor) and kidney (V2 receptor) plasma membranes in a competitive manner and that it is about 100 times more selective for V2 receptors. K d value for [3H]-AVP in rat liver is 1.1 nM; in rat kidney is 1.38 nM. The K d of [3H]-AVP is reduced significantly in both rat liver and kidney in the presence of Mozavaptan (K d of 2.47 nM and 5.51 nM for V1 receptor at the doses of 0.3 μM and 1 μM.respectively; K d of 2.4 nM and 4.03 nM for V2 receptor at the doses of 0.3 μM and 1 μM.respectively).
Mozavaptan (OPC-31260; 1-30 mg/kg; oral administration; hydrated conscious rats) treatment dose-dependently increases urine flow and decreased urine osmolality.
Mozavaptan (OPC-31260; 10-100 μg/kg; intravenous injection; male Sprague-Dawley rats) treatment inhibits the antidiuretic action of exogenously administered arginine vasopressin (AVP) in water-loaded, alcohol-anaesthetized rats in a dose-dependent manner.
| Animal Model: | Hydrated conscious rats (300-350 g) |
| Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg |
| Administration: | Oral administration |
| Result: | Dose-dependently increased urine flow and decreased urine osmolality. |
莫扎伐普坦盐酸盐 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-123593R | 莫扎伐普坦盐酸盐 | 138470-70-9 | 5 mg | 900 |
| 2026-09-15 | HY-123593R | 莫扎伐普坦盐酸盐 | 138470-70-9 | 10 mg | 1350 |
